Osimertinib, an irreversible next-generation EGFR tyrosine kinase inhibitor, exerts antitumor activity in various preclinical nsclc models harboring the uncommon EGFR mutations G719X or L861Q or S768I

Nicolas Floch, Sangbin Lim, Sue Bickerton, Afshan Ahmed, Jonathan Orme, Jelena Urosevic, Matthew J. Martin, Darren A.E. Cross, Byoung Chul Cho, Paul D. Smith

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Osimertinib, an irreversible next-generation EGFR tyrosine kinase inhibitor, exerts antitumor activity in various preclinical nsclc models harboring the uncommon EGFR mutations G719X or L861Q or S768I'. Together they form a unique fingerprint.

Medicine & Life Sciences